| Is p53 polymorphism maintained by natural selection? G Beckman, R Birgander, A Själander, N Saha, PÅ Holmberg, A Kivelä, ... Human heredity 44 (5), 266-270, 1994 | 465 | 1994 |
| Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA M Wieloch, A Själander, V Frykman, M Rosenqvist, N Eriksson, ... European heart journal 32 (18), 2282-2289, 2011 | 352 | 2011 |
| p53 polymorphisms and haplotypes in breast cancer A Sjalander, R Birgander, G Hallmans, S Cajander, P Lenner, L Athlin, ... Oxford University Press 17 (6), 1313-1316, 1996 | 264 | 1996 |
| Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia B Simonsson, T Gedde-Dahl, B Markevärn, K Remes, J Stentoft, ... Blood, The Journal of the American Society of Hematology 118 (12), 3228-3235, 2011 | 250 | 2011 |
| Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia M Ilander, U Olsson-Strömberg, H Schlums, J Guilhot, O Brück, ... Leukemia 31 (5), 1108-1116, 2017 | 243 | 2017 |
| Prevalence of subclinical coronary artery atherosclerosis in the general population G Bergström, M Persson, M Adiels, E Björnson, C Bonander, H Ahlström, ... Circulation 144 (12), 916-929, 2021 | 201 | 2021 |
| Outcomes in a warfarin-treated population with atrial fibrillation F Björck, H Renlund, GYH Lip, P Wester, PJ Svensson, A Själander JAMA cardiology 1 (2), 172-180, 2016 | 181 | 2016 |
| Safety and efficacy of well managed warfarin V Sjögren, B Grzymala-Lubanski, H Renlund, L Friberg, GYH Lip, ... Thrombosis and haemostasis 113 (06), 1370-1377, 2015 | 179 | 2015 |
| p53 polymorphisms and haplotypes in different ethnic groups A Själander, R Birgander, A Kivelä, G Beckman Human heredity 45 (3), 144-149, 1995 | 171 | 1995 |
| P53 polymorphisms and haplotypes in lung cancer R Birgander, A Själander, A Rannug, AK Alexandrie, MI Sundberg, ... Carcinogenesis 16 (9), 2233-2236, 1995 | 158 | 1995 |
| Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome J Richter, S Söderlund, A Lübking, A Dreimane, K Lotfi, B Markevärn, ... J Clin Oncol 32 (25), 2821-2823, 2014 | 150 | 2014 |
| Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry M Höglund, F Sandin, K Hellström, M Björeman, M Björkholm, M Brune, ... Blood, The Journal of the American Society of Hematology 122 (7), 1284-1292, 2013 | 150 | 2013 |
| Atrial fibrillation patients do not benefit from acetylsalicylic acid S Själander, A Själander, PJ Svensson, L Friberg Europace 16 (5), 631-638, 2014 | 133 | 2014 |
| P53 germ line haplotypes associated with increased risk for colorectal cancer A Själander, R Birgander, L Athlin, R Stenling, J Rutegård, L Beckman, ... Carcinogenesis 16 (7), 1461-1464, 1995 | 131 | 1995 |
| p53 polymorphisms and haplotypes show distinct differences between major ethnic groups A Själander, R Birgander, N Saha, L Beckman, G Beckman Human heredity 46 (1), 41-48, 1996 | 117 | 1996 |
| Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta‐analysis A Själander, JH Jansson, D Bergqvist, H Eriksson, B Carlberg, ... Journal of internal medicine 263 (1), 52-60, 2008 | 101 | 2008 |
| Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study T Dahlén, G Edgren, M Lambe, M Höglund, M Björkholm, F Sandin, ... Annals of internal medicine 165 (3), 161-166, 2016 | 99 | 2016 |
| Association between the p21 codon 31 A1 (arg) allele and lung cancer A Själander, R Birgander, A Rannug, AK Alexandrie, G Tornling, ... Human heredity 46 (4), 221-225, 1996 | 91 | 1996 |
| Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics J Wallvik, A Själander, L Johansson, Ö Bjuhr, JH Jansson Scandinavian Journal of Primary Health Care 25 (2), 123-128, 2007 | 74 | 2007 |
| Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population A Själander, G Engström, E Berntorp, P Svensson Journal of internal medicine 254 (5), 434-438, 2003 | 73 | 2003 |
